Literature DB >> 456401

Pharmacokinetics of quinidine related to plasma protein binding in man.

D Fremstad, O G Nilsen, L Storstein, J Amlie, S Jacobsen.   

Abstract

The disposition and plasma protein binding of quinidine after intravenous administration were studied in 13 healthy subjects. Plasma protein binding, expressed as the fraction of quinidine unbound ranged from 0.134--0.303 (mean 0.221). Elimination rate constant (beta) varied from 0.071 to 0.146 h-1 (mean 0.113), and apparent volume of distribution (Vbeta) varied from 1.39--3.20 1 . kg-1 beta (mean 2.27). Total body clearance was 2.32--6.49 ml min-1 . kg-1. There was a positive linear correlation between the plasma fraction of unbound quinidine and both V beta (r = 0.885, p less than 0.01) and total body clearance (r = 0.668, p less than 0.05). No significant correlation existed between the fraction of unbound quinidine in plasma and the elimination rate constant. The results show that both the apparent volume of distribution and total body clearance of quinidine are proportional to the unbound fraction in plasma. This implies that the total plasma concentration of quinidine at steady state will change with alterations in plasma binding, whilst the concentration of unbound compound and its elimination rate will remain unaffected.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 456401     DOI: 10.1007/bf00563104

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  22 in total

1.  The effect of congestive heart failure on quinidine pharmacokinetics.

Authors:  W G Crouthamel
Journal:  Am Heart J       Date:  1975-09       Impact factor: 4.749

2.  Factors influencing conversion of chronic atrial fibrillation with special reference to serum quinidine concentration.

Authors:  R E BALL; M SOKOLOW
Journal:  Circulation       Date:  1956-10       Impact factor: 29.690

3.  Serum albumin and lipoproteins as the quinidine binding molecules in normal human sera.

Authors:  O G Nilsen
Journal:  Biochem Pharmacol       Date:  1976-05-01       Impact factor: 5.858

4.  Disposition kinetics of dihydroquinidine following quinidine administration.

Authors:  C T Ueda; B J Williamson; B S Dzindzio
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1976-06

5.  Early and late results of conversion of atrial fibrillation with quinidine. A clinical and hemodynamic study.

Authors:  G Cramér
Journal:  Acta Med Scand Suppl       Date:  1968

6.  Increased plasma binding of quinidine after surgery: a preliminary report.

Authors:  D Fremstad; K Bergerud; J F Haffner; P K Lunde
Journal:  Eur J Clin Pharmacol       Date:  1976       Impact factor: 2.953

7.  Binding of quinidine in sera with different levels of triglycerides, cholesterol, and orosomucoid protein.

Authors:  O G Nilsen; P Leren; I Aakesson; S Jacobsen
Journal:  Biochem Pharmacol       Date:  1978-03-15       Impact factor: 5.858

8.  Absolute quinidine bioavailability.

Authors:  C T Ueda; B J Williamson; B S Dzindzio
Journal:  Clin Pharmacol Ther       Date:  1976-09       Impact factor: 6.875

9.  Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect.

Authors:  A Yacobi; J A Udall; G Levy
Journal:  Clin Pharmacol Ther       Date:  1976-05       Impact factor: 6.875

10.  Binding of quinidine to plasma proteins in normal subjects and in patients with hyperlipoproteinemias.

Authors:  R E Kates; T D Sokoloski; T J Comstock
Journal:  Clin Pharmacol Ther       Date:  1978-01       Impact factor: 6.875

View more
  6 in total

1.  Pharmacokinetics of quinidine in male patients. A population analysis.

Authors:  C N Verme; T M Ludden; W A Clementi; S C Harris
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

Review 2.  Disease-induced changes in the plasma binding of basic drugs.

Authors:  K M Piafsky
Journal:  Clin Pharmacokinet       Date:  1980 May-Jun       Impact factor: 6.447

3.  The pharmacokinetics and pharmacodynamics of quinidine and 3-hydroxyquinidine.

Authors:  R A Wooding-Scott; J Smalley; J Visco; R L Slaughter
Journal:  Br J Clin Pharmacol       Date:  1988-10       Impact factor: 4.335

4.  Plasma protein binding of imipramine in patients with rheumatoid arthritis.

Authors:  C B Kristensen
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

5.  Analysis of nonlinear tissue distribution of quinidine in rats by physiologically based pharmacokinetics.

Authors:  H Harashima; Y Sawada; Y Sugiyama; T Iga; M Hanano
Journal:  J Pharmacokinet Biopharm       Date:  1985-08

Review 6.  Prediction of the disposition of nine weakly acidic and six weakly basic drugs in humans from pharmacokinetic parameters in rats.

Authors:  Y Sawada; M Hanano; Y Sugiyama; T Iga
Journal:  J Pharmacokinet Biopharm       Date:  1985-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.